Cellular Senescence and COVID-19 Long-Hauler Syndrome

Overview

Información sobre este estudio

The purpose of this study is to test if senescent cells and their secretome contribute to Long-Hauler Syndrome and if a clinical trial of senolytic drugs, which selectively eliminate senescent cells, should be initiated. 

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria - Longhaulers Cohort:

Subject population: 100 men and women who have been diagnosed with Post-COVID syndrome.

  • Ability to give informed consent or LAR.
  • At least 18 years old.
  • Ability of subject or LAR to read and speak the English language.
  • Positive PCR or antibody test within 18 months of initial study visit.
  • Patient of the Long-Hauler Syndrome clinic and differential diagnosis of Long-Hauler Syndrome.

Exclusion Criteria:

  • Any potential participant who refuses medical record review.
  • Pregnant females.
  • Incarcerated individuals.
  • Inability to cooperate or any medical condition that, in the opinion of the investigator, interferes with the evaluation of the study objectives or increases the subject’s risk by participating in the study.
  • Patient is unfit to participate at the discretion of the Principal Investigator.

Inclusion Criteria - Control Cohort:

Subject population: 50 men and women who have not had a known case of COVID or Longhauler’s syndrome.

  • Ability to give informed consent or LAR.
  • At least 18 years old.
  • Ability of subject or LAR to read and speak the English language.

Exclusion Criteria:

  • Known case of COVID-19.
  • Any potential participant who refuses medical record review.
  • Pregnant females.
  • Incarcerated individuals.
  • Inability to cooperate or any medical condition that, in the opinion of the investigator, interferes with the evaluation of the study objectives or increases the subject’s risk by participating in the study.
  • Patient is unfit to participate at the discretion of the Principal Investigator.

Inclusion Criteria - COVID-19 Control Cohort:

Subject population: 50 men and women who have had a known case of COVID, but not Longhauler’s syndrome.

  • Ability to give informed consent or LAR.
  • At least 18 years old.
  • Ability of subject to read and speak the English language.
  • Known case of COVID-19.

Exclusion Criteria:

  • Known Longhauler’s syndrome/Post-COVID
  • Any potential participant who refuses medical record review.
  • Pregnant females.
  • Incarcerated individuals.
  • Inability to cooperate or any medical condition that, in the opinion of the investigator, interferes with the evaluation of the study objectives or increases the subject’s risk by participating in the study.

Eligibility last updated 11/19/21. Questions regarding updates should be directed to the study team contact.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

James Kirkland, M.D., Ph.D.

Abierto para la inscripción

Contact information:

Tamara Evans

(507) 284-1004

Evans.Tamara@mayo.edu

More information

Publicaciones

Publications are currently not available
.
CLS-20510125

Mayo Clinic Footer